Login to Your Account



Analysts spin, balance Meniere's data; after near miss, Otonomy heads to phase III

By Randy Osborne
Staff Writer

Friday, May 22, 2015

With primary endpoint-missing phase IIb data in hand, Otonomy Inc. CEO David Weber said he is "more confident today" that OTO-104 for Meniere's disease is a viable product, and the company will be meeting with the FDA to talk about the planned phase III program.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription